Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
1.420
+0.068 (5.04%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 60 employees as of December 31, 2024. The number of employees decreased by 6 or -9.09% compared to the previous year.
Employees
60
Change (1Y)
-6
Growth (1Y)
-9.09%
Revenue / Employee
$86,233
Profits / Employee
-$315,267
Market Cap
51.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ARMP News
- 5 weeks ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 6 weeks ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 6 weeks ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Structural Biology Publication - PRNewsWire